Insempra appoints two new members to its Scientific Advisory Board

Insempra appoints two new members to Scientific Advisory Board

28.11.2022 · 3 min. read

, Linkedin, Twitter

Munich/London, 25 October 2022Insempra, a biology-powered company enabling businesses to make superior products in partnership with nature, today announces the appointment of Professor Michael Jewett and Professor Paul Freemont to its scientific advisory board (SAB). The SAB is comprised of world-renowned academics to provide scientific review and high-level counsel on the Company’s R&D to advance its development of intrinsically sustainable ingredients at scale. 

The SAB works closely with Insempra’s leadership team as the Company advances its nutrition, beauty and fibers platforms to accelerate the discovery, design and development of multi-functional superior ingredients for wide-scale market application.

Jens Klein, CEO of Insempra, commented: “We are honored to have these accomplished scientific leaders join Insempra’s Scientific Advisory Board. These individuals have made significant contributions and pioneered breakthroughs in biological engineering and, together, they bring a wealth of knowledge and experience to Insempra, as we work to develop our superior ingredient product platforms. We look forward to harnessing the knowledge and experience of these outstanding individuals as we advance our platform technology in precision fermentation and cell-free bioengineering and our ongoing research and development efforts in a number of large-scale market applications.

Further details on the new SAB members

Professor Michael Jewett is a Professor of Chemical and Biological Engineering, and Director of the Center for Synthetic Biology at Northwestern University. Professor Jewett’s lab focuses on advancing synthetic biology research in support of planet and societal health. He is the recipient of the NIH Pathway to Independence Award, David and Lucile Packard Fellowship in Science and Engineering, Camille-Dreyfus Teacher-Scholar Award, and a Finalist for the Blavatnik National Awards for Young Scientists, among others. He is the co-founder of SwiftScale Biologics, Stemloop, Inc., Pearl Bio, and Design Pharmaceuticals. Professor Jewett is a Fellow of AIMBE, AAAS, and NAI.

Professor Paul Freemont is Co-founder of the Imperial College Centre for Synthetic Biology (2009) and Co-founder/Co-director of the National UK Innovation and Knowledge Centre for Synthetic Biology (SynbiCITE; since Oct 2013) at Imperial College London. The Centre aims to enable synthetic biology research in application areas like biosensors, biosynthesis, bioprocessing and metabolic and genome engineering and enable the translation of new synthetic biology technologies into start-ups, SMEs and industry. Professor Freemont’s research interests are focused on developing synthetic biology foundational tools, automation and biofoundries for specific applications including biosensing and metabolic engineering. He is the author of over 300 scientific publications and is an elected member of the European Molecular Biology Organisation and also a Fellow of the Royal Societies of Biology, Chemistry and Medicine and is an Honorary Fellow of the Royal College of Art.

About Insempra

Insempra is a biology-powered company enabling businesses to make superior products with nature. We combine bioscience and technology to grow matter for new and better products.

For too long, businesses have relied on chemical industrialization processes and petrochemicals, depleting our planet’s limited resources. That’s why we are committed to drive the regenerative revolution to manufacture at scale in collaboration with nature.

Led by a hand-picked team of biologists, technologists and entrepreneurs with rebel hearts, Insempra is here to create a new school of thought and collective action. The time to restore the balance between people and the planet is now. We don’t wait for change. We do what needs to be done to grow a better future.

Enquiries

FTI Consulting

Ann Bartling / Michael Trace

Tel: +44/(0)20/3727 1000

insempra@fticonsulting.com

Posted by Nicole Laurence

Latest news

Insempra and BII collaborate to accelerate biotech innovation

Insempra today announces the collaboration with the BioInnovation Institute (BII). The collaboration between Insempra and the BII will help identify early-stage innovation and technology to advance the development of sustainable solutions for the benefit of people, society and the planet.

Meet Tim Zeiske, Head of Data Science, Innovation & Automation Lipids

Meet Tim Zeiske, Insempra's Head of Data Science, Innovation & Automaton Lipids
Cell-Free Technology established at Insempra

Cell-Free Technology established at Insempra

Scent, flavor, color, and other properties are what make our favorite food and personal care products particularly special. Increasingly, these ingredients come from exploitative processes. At Insempra we build microbial strains that can convert renewable feedstocks to natural ingredients by precision fermentation - a natural process that is non-exploitative.

Meet Luisa Gronenberg, Head of R&D for Functional Ingredients & Strain Engineering

Meet Luisa Gronenberg, Insempra's Head of R&D for Functional Ingredients & Strain Engineering.

10 things Insempra looks for when scouting new tech

Finding partners that are a good fit for Insempra’s model means analyzing loads of academic institutions, SMEs, start-ups and innovative business units at corporations. We have created a framework of ten criteria to evaluate new technologies in order to make decisions more quickly. We use this framework while looking for new potential partners and collaborators.

Meet Dr. Volker Wagner-Solbach, Head of Scale Up, Supply Chain & Procurement

Meet Dr. Volker Wagner-Solbach, Insempra's Head of Scale Up, supply chain and procurement.

Q&A with Jens Klein, CEO & Founder of Insempra

Meet Jens Klein, CEO & Founder of Insempra
Insempra Fibers

Insempra, formerly Origin.Bio, announces strategic investment in Solena Materials

Strategic investment to support the foundation of Solena Materials, a spin-out from Imperial College London, accelerating the development of synthetic fibers for high-performance, intrinsically sustainable clothing

Origin.bio and Carbocycle join forces to revolutionize the chemical industry towards a regenerative future

Origin.bio, a biotechnology company, and the team of Carbocycle, a spin-off from Columbia University, are joining forces to produce tailor-made lipids torevolutionize the chemical industry towards a regenerative future.

This Company Is Freeing Manufacturers From Petrochemicals With Biology

Origin.Bio announced today that it has secured $15 million of funding led by EQT Ventures. The company plans to use the funding to expand technology and bring sustainable ingredients to brands all over the world.

Nature grows
— and so does our community.

Read more